Enliven Therapeutics is based in Boulder, Colorado. It has raised $230M in total funding. Latest round: Growth.
Enliven Therapeutics funding overview
Enliven Therapeutics is based in Boulder, Colorado. Enliven Therapeutics has raised $230M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Growth announced in March 2024. The round record for Enliven Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Cormorant Asset Management, Surveyor Capital, Boxer Capital, Janus Henderson Investors, Logos Capital. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Enliven Therapeutics funding
How much has Enliven Therapeutics raised?
Enliven Therapeutics has raised $230M in total disclosed funding across the rounds on record.
Who has invested in Enliven Therapeutics?
Cormorant Asset Management, Surveyor Capital, Boxer Capital, Janus Henderson Investors, Logos Capital are named among the investors backing Enliven Therapeutics.
What was the latest Enliven Therapeutics funding round?
The most recent disclosed round is a Growth, announced in March 2024.
Where is Enliven Therapeutics based?
Enliven Therapeutics is based in Boulder, Colorado.
When did Enliven Therapeutics last raise?
The last disclosed Enliven Therapeutics round closed in March 2024 at Growth.
Enliven Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Boulder below to benchmark round size and investor mix.
